Di Simone N, Crowley W F, Wang Q F, Sluss P M, Schneyer A L
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston 02114, USA.
Endocrinology. 1996 Feb;137(2):486-94. doi: 10.1210/endo.137.2.8593793.
Although ovarian cancer is the most common gynecological malignancy with a relatively poor 5-yr survival record, the mechanism(s) by which these tumors arise is not well understood. A role for inhibins and activins in regulating this transformation is suggested by the detection of circulating alpha or dimeric inhibin in some patients with ovarian cancer and by the alpha inhibin knockout mouse, in which development of gonadal tumors in 100% of homozygotes is associated with greatly elevated activin levels. To develop diagnostic tools with greater specificity for ovarian cancers, the present study was targeted at characterizing the biosynthetic capacity of the epithelial ovarian cancer cell lines from the American Type Culture Collection with respect to inhibin, activin, the related activin-binding protein follistatin (FS), and activin receptor type II. In addition, the functional capacity of this system was investigated by examining the ability of activin and FS to modulate cellular proliferation. All six cell lines contained abundant messenger RNA (mRNA) for activin receptor type II, but no inhibin alpha-subunit mRNA was detected in any cell line. Two cell lines contained mRNA for activin beta B-subunit (CaOV4 and SKOV3), one cell line contained beta A-subunit mRNA (SW626), and one cell line contained both (ES2); the latter also contained FS mRNA. FS mRNA was detected in another cell line (PA-1) that contained no detectable activin beta-subunit mRNA. Finally, one cell line (CaOV3) contained neither beta-subunit nor FS mRNA. Protein secretion was also examined. Consistent with the mRNA studies, the two cell lines containing FS mRNA secreted FS (PA-1 and ES2 cells), whereas three of the remaining lines secreted activin (A or B). In the cell line containing neither FS nor beta-subunit mRNA, no FS or activin could be detected. Finally, none of the cell lines secreted detectable immunoreactive inhibin. The effects of exogenous activin and FS on cellular proliferation were examined in these cell lines. No response was detected in the two cell lines that secreted FS (PA-1 and ES2). For the four cell lines not synthesizing FS, treatment with activin (1-100 ng/ml) resulted in an increase, whereas FS treatment (1-100 ng/ml) resulted in a decrease in cellular proliferation, as determined by [3H]thymidine incorporation. The response to activin correlated negatively with endogenous activin production, suggesting that autocrine activin production may be involved with cell proliferation. The differential expression and production of inhibin/activin subunits, activin receptors, and follistatin as well as the range of responses to exogenous activin among six ovarian epithelial cancer cell lines suggest that this family of hormones may be important in regulating cell proliferation in the ovary. Whether primary tumors have the same profile and the degree to which these results can be generalized to additional forms of ovarian cancer remain to be determined.
尽管卵巢癌是最常见的妇科恶性肿瘤,其5年生存率相对较低,但这些肿瘤的发生机制尚未完全明确。一些卵巢癌患者体内循环中检测到α或二聚体抑制素,以及α抑制素基因敲除小鼠(其中100%的纯合子性腺肿瘤的发生与激活素水平大幅升高有关),提示抑制素和激活素在调节这种转变中发挥作用。为了开发对卵巢癌具有更高特异性的诊断工具,本研究旨在表征美国典型培养物保藏中心的上皮性卵巢癌细胞系在抑制素、激活素、相关的激活素结合蛋白卵泡抑素(FS)和激活素II型受体方面的生物合成能力。此外,通过检测激活素和FS调节细胞增殖的能力来研究该系统的功能。所有六种细胞系均含有丰富的激活素II型受体信使核糖核酸(mRNA),但在任何细胞系中均未检测到抑制素α亚基mRNA。两种细胞系含有激活素βB亚基mRNA(CaOV4和SKOV3),一种细胞系含有βA亚基mRNA(SW626),一种细胞系同时含有两者(ES2);后者还含有FS mRNA。在另一种未检测到激活素β亚基mRNA的细胞系(PA-1)中检测到FS mRNA。最后,一种细胞系(CaOV3)既不含有β亚基也不含有FS mRNA。还检测了蛋白质分泌情况。与mRNA研究结果一致,含有FS mRNA的两种细胞系分泌FS(PA-1和ES2细胞),而其余三种细胞系分泌激活素(A或B)。在既不含有FS也不含有β亚基mRNA的细胞系中,未检测到FS或激活素。最后,没有一个细胞系分泌可检测到的免疫反应性抑制素。在这些细胞系中检测了外源性激活素和FS对细胞增殖的影响。在分泌FS的两种细胞系(PA-1和ES2)中未检测到反应。对于四种不合成FS的细胞系,用激活素(1-100 ng/ml)处理导致细胞增殖增加,而用FS处理(1-100 ng/ml)导致细胞增殖减少,这通过[3H]胸苷掺入法测定。对激活素的反应与内源性激活素产生呈负相关,提示自分泌激活素产生可能与细胞增殖有关。六种卵巢上皮癌细胞系中抑制素/激活素亚基、激活素受体和卵泡抑素的差异表达和产生,以及对外源性激活素的反应范围表明,这一激素家族可能在调节卵巢细胞增殖中起重要作用。原发性肿瘤是否具有相同的特征以及这些结果能够推广到其他形式卵巢癌的程度仍有待确定。